Jubilant Ingrevia Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Jubilant Ingrevia (NSE: JUBLINGAS) is preparing to announce its Q4 FY26 (January–March 2026) financial results for the period ended March 31, 2026. With the stock trading at Rs 380 — against a 52-week high of Rs 520 and a 1-year return of -22% — the Q4 FY26 results will be a pivotal event for investors assessing their position heading into FY27.

Analyst consensus estimates for Q4 FY26 stand at Rs 1,000–1,100 Cr in revenue and Rs 55–75 Cr in profit after tax, with margin expectations of EBITDA 14–16%. The key growth metric of CDMO Revenue +25–30% YoY will be closely watched alongside the management’s FY27 guidance — which analysts consider more important than the reported Q4 number in the current macro environment.

Get free investment predictions and live Q4 result alerts on Univest.

Jubilant Ingrevia Q4 Results 2026 Date

The Jubilant Ingrevia Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to consider and approve the audited consolidated and standalone financial results for the quarter and full year ended March 31, 2026 and consider recommending a final dividend.

Here is the broader Q4 FY26 earnings calendar for major Indian companies:

For more Q4 FY26 results previews across all sectors, visit Univest Blogs.

Why This Quarter Matters

Q4 FY26 (January–March 2026) is the most important quarter of any financial year — it determines the full-year FY26 financial outcome, sets the earnings base for FY27 analyst estimates, and triggers final dividend announcements. For Jubilant Ingrevia, with a 1-year stock return of -22%, this quarter’s results and FY27 guidance are critical for determining whether the stock can begin a meaningful recovery or faces continued pressure.

Beyond the headline revenue and PAT numbers, investors will focus on three things: (1) whether FY27 guidance matches the consensus expectation of CDMO Revenue +25–30% YoY, (2) whether the margin of EBITDA 14–16% is sustainable or under pressure, and (3) the dividend announcement of Rs 3 per share. A positive surprise on any two of these three parameters could drive a meaningful post-results re-rating.

Jubilant Ingrevia Q4 FY26 Earnings Estimates

Figure 2: Jubilant Ingrevia Q4 FY26 Analyst Estimates — Revenue: Rs 1,000–1,100 Cr | PAT: Rs 55–75 Cr | Margin: EBITDA 14–16% | Growth: CDMO Revenue +25–30% YoY

Access premium SEBI-registered research on Univest.

Brokerages including MOFSL, YES Securities, and JM Financial have published their Q4 FY26 preview estimates for Jubilant Ingrevia. The consensus projects Rs 1,000–1,100 Cr in revenue (versus Q3 FY26 actual of Rs 920 Cr) and PAT of Rs 55–75 Cr (versus Q3 actual of Rs 50 Cr). A beat on revenue combined with margin expansion would be the most positive scenario for the stock.

Screen Jubilant Ingrevia live fundamentals, FII/DII activity, and analyst upgrades on Univest Screener.

5 Key Factors That Will Drive Jubilant Ingrevia Q4 FY26 Performance

1. Q4 FY26 Revenue Estimate: Rs 1,000–1,100 Cr

Analyst consensus expects Jubilant Ingrevia to report Rs 1,000–1,100 Cr in Q4 FY26. CDMO Revenue +25–30% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.

2. PAT Estimate and Margin Trajectory

Analyst consensus expects Jubilant Ingrevia to report Rs 1,000–1,100 Cr in Q4 FY26. CDMO Revenue +25–30% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.

3. Key Growth Driver: CDMO Revenue +25–30% YoY

Analyst consensus expects Jubilant Ingrevia to report Rs 1,000–1,100 Cr in Q4 FY26. CDMO Revenue +25–30% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.

4. Dividend and Capital Allocation

Analyst consensus expects Jubilant Ingrevia to report Rs 1,000–1,100 Cr in Q4 FY26. CDMO Revenue +25–30% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.

5. FY27 Guidance — The Most Critical Catalyst

Analyst consensus expects Jubilant Ingrevia to report Rs 1,000–1,100 Cr in Q4 FY26. CDMO Revenue +25–30% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.

5 Risks to Watch in Jubilant Ingrevia Q4 FY26

1. US Tariff Macro Headwinds

The 26% US reciprocal tariff on Indian goods — announced April 2, 2026 — has created FII outflow pressure across Indian equities. For Jubilant Ingrevia, indirect impacts include lower institutional ownership and compresed earnings multiples even if the company’s own exports or supply chain are not directly affected.

2. Results Miss Versus Estimates

If Jubilant Ingrevia’s Q4 FY26 results miss analyst estimates of Rs 1,000–1,100 Cr revenue and Rs 55–75 Cr PAT, the stock could correct sharply. Investors should have pre-defined exit levels and position sizing appropriate for the earnings uncertainty.

3. FY27 Guidance Disappointment

If management’s FY27 guidance falls below the Street’s expectations — even with an in-line Q4 — the stock may decline on forward estimate cuts. Guidance credibility is a function of track record; any slippage from prior guidance makes the market discount new guidance aggressively.

4. Sector-Level Competitive Pressure

The Specialty Chemicals / CDMO / Pyridine sector faces intensifying competitive dynamics from both domestic capacity additions and international competition. Jubilant Ingrevia’s ability to maintain pricing power and market share in this environment is a critical long-term risk factor.

5. FII Selling and Liquidity Risk

With FII holding at varying levels, global risk-off events can trigger concentrated institutional selling that disconnects price from fundamentals. Mid-and small-cap stocks are particularly vulnerable to liquidity-driven moves on results day.

Jubilant Ingrevia Share Price and Analyst Ratings

Jubilant Ingrevia is trading at Rs 380 as of April 2026, against a 52-week high of Rs 520 and a 52-week low of Rs 310. The 1-year return of -22% reflects the macro headwinds of FY26 — US-India tariff uncertainty, FII outflows, and sector-specific pressures. Analyst consensus 12-month targets range from Rs 520 to Rs 500, implying potential recovery from current levels contingent on Q4 FY26 execution and FY27 guidance.

Download the Univest iOS App or Univest Android App to track Jubilant Ingrevia live price, charts, and receive real-time research alerts from SEBI-registered analysts.

Conclusion

Jubilant Ingrevia Q4 FY26 results on May 2026 (Expected) will be a key earnings event for investors monitoring the Specialty Chemicals / CDMO / Pyridine sector. With analyst consensus projecting revenue of Rs 1,000–1,100 Cr and PAT of Rs 55–75 Cr, the stock at Rs 380 offers a risk-reward profile that depends on execution delivery and FY27 guidance credibility. FY27 guidance — revenue growth bands, margin targets, and capex plans — will be the single most important post-results catalyst. For more Q4 FY26 previews, visit 

Univest Blogs.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions. For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: What is the Jubilant Ingrevia Q4 results 2026 date?

The Jubilant Ingrevia Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve the audited Q4 FY26 financial results and consider a final dividend recommendation.

Q: What is the Jubilant Ingrevia Q4 FY26 PAT estimate?

Analysts estimate Jubilant Ingrevia Q4 FY26 PAT in the range of Rs 55–75 Cr, based on revenue of Rs 1,000–1,100 Cr and margin of EBITDA 14–16%. Actual results may differ from consensus estimates.

Q: What is Jubilant Ingrevia’s share price ahead of Q4 results?

Jubilant Ingrevia is trading at Rs 380 as of April 2026. The 52-week high is Rs 520 and the 52-week low is Rs 310. The 1-year return is -22% and market capitalisation is Rs 6,050 Cr.

Q: Will Jubilant Ingrevia declare a dividend in Q4 FY26?

Jubilant Ingrevia is expected to consider Rs 3 per share at the Q4 FY26 board meeting. The quantum will be confirmed on the results date.

Q: Which analysts have a Buy rating on Jubilant Ingrevia?

MOFSL (target Rs 500), JM Financial (target Rs 480), YES Securities (target Rs 520). Consult a SEBI-registered financial advisor before making any investment decision.

Q: What were Jubilant Ingrevia Q3 FY26 results?

Jubilant Ingrevia reported Q3 FY26 revenue of Rs 920 Cr and PAT of Rs 50 Cr, with margin at EBITDA 14.5%. These Q3 actuals form the sequential base against which Q4 FY26 estimates are benchmarked.

Q: When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026 — reporting PAT of Rs 13,718 crore and revenue of Rs 70,698 crore. For the full TCS preview visit https://univest.in/blogs/tcs-q4-results-2026-date-preview. Infosys Q4 FY26 results are scheduled for April 23, 2026 — FY27 CC revenue guidance is the critical watch. Read the full analysis at https://univest.in/blogs/infosys-q4-results-2026-date-preview.

Q: Is Jubilant Ingrevia a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. Jubilant Ingrevia has both compelling factors — CDMO order delivery; pyridine recovery — and genuine near-term risks including US tariff macro headwinds and FY27 guidance uncertainty. Analyst consensus targets range from Rs 520 to Rs 500. Consult a SEBI-registered financial advisor before investing.

Recent Article

Natural Capsules Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

National Fertilizers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

National Aluminium Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Narmada Agrobase Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook